Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Feb 11, 2022 4:55pm
200 Views
Post# 34421991

RE:RE:RE:RE:RE:RE:RE:Uploaded by THTX

RE:RE:RE:RE:RE:RE:RE:Uploaded by THTX

I just think scientists are generally optimistic about their work up until the sh*t hits the fan. So probably the sh*t hasn't hit the fan yet, I think most of us are assuming that at this point in time.


scarlet1967 wrote: We can interpret it as we would like , my biased interpretation is using the term "miracle cure" is quite an statement for a scientist who is working in the field but the main issue is very few people get the chance to make their own interpretation !
It would be interesting how many views this clip would generate? My guess not many at all which is the issue the company is so reluctant to deal with. Now at some point soon they will release the phase1a data and I really hope firstly they make sure the message is received by as broad audience as possible and secondly the average retail investors understand the results of course the biased presumption is the results are good. Point is if that is the case they have to make sure the perception is as good as the result.
 

palinc2000 wrote: She didn.t say they had been succesful but that is the goal....


longterm56 wrote: Perfect example of confirmation bias ... or  "we hear what we want to hear".  Very few people would interpret her story about her career goal as saying "Theratech has a miracle drug" ... so palinc ... you're special! 

   -LT



 or
palinc2000 wrote: She said that joining THTX could allow her to fulfill her dream of saving cancer patients,,She then said   that her objective was to associate herself with the right people to develop a miracle drug........She did not say TH 1902 but this is what THTX is working on ......I maintain my post!!!


longterm56 wrote: Your post seems to want us to believe she called TH1902 a "miracle drug".  She didn't.  She didn't even mention any specific drug. She was talking about her "career aspirations".  You kind of pulled it out of context. 

  -LT


palinc2000 wrote: She said'' Miracle Drug ""  

 

 

 

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse